Peer-reviewed veterinary case report
Blood test with 3 markers helps diagnose and monitor chronic gut
By Estruch, Juan et al.·Published in Journal of veterinary internal medicine·2021·Vetica Labs, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with chronic gastrointestinal issues, including inflammatory bowel disease (IBD), were tested for specific markers in their blood to help diagnose their condition and monitor treatment effectiveness. The study found that dogs with IBD had significantly higher levels of these markers compared to healthy dogs, and the levels decreased after treatment, indicating improvement. This new test could help veterinarians better identify and manage dogs with chronic enteropathies, making it easier to track their recovery.
People also search for: dog chronic diarrhea treatment · inflammatory bowel disease in dogs · blood test for dog gastrointestinal issues
Abstract
BACKGROUND: Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. OBJECTIVE: To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment-related responses. ANIMALS: One hundred fifty-seven dogs with CE/inflammatory bowel disease (IBD), 24 dogs non-IBD gastrointestinal disorders, and 33 normal dogs. METHODS: Prospective, multicenter, clinical study that enrolled dogs with gastrointestinal disorders. Serum sample collected at enrollment and up to 3 months follow-up measuring OmpC (ACA), canine calprotectin (ACNA), and gliadin-derived peptides (AGA) by ELISA. RESULTS: Seropositivity was higher in CE/IBD than normal dogs (66% vs 9% for ACA; 55% vs 15% for ACNA; and 75% vs 6% for AGA; P < .001). When comparing CE/IBD with non-IBD disease, ACA and ACNA displayed discriminating properties (66%, 55% vs 12.5%, 29% respectively) while AGA separated CE from normal cohorts (54% vs 6%). A 3-marker algorithm at cutoff of ACA > 15, ACNA > 6, AGA > 60 differentiates CE/IBD and normal dogs with 90% sensitivity and 96% specificity; and CE/IBD and non-IBD dogs with 80% sensitivity and 86% specificity. Titers decreased after treatment (47%-99% in ACA, 13%-88% in ACNA, and 30%-85% in AGA), changes that were concurrent with clinical improvements. CONCLUSION AND CLINICAL IMPORTANCE: An assay based on combined measurements of ACA, ACNA, and AGA is useful as a noninvasive diagnostic test to distinguish dogs with CE/IBD. The test also has the potential to monitor response to treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33960552/